ROCHE HOLDING AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 222.3 CHF | +0.45% |
|
+0.77% | -9.08% |
Presentation Operator MessageOperator (Operator)Kindly note that the webinar is being recorded...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Sector
Pharmaceuticals
Calendar
2024-05-14
- BofA Securities Health Care Conference
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A+
Sell
Buy
Mean consensus
HOLD
Number of Analysts
19
Last Close Price
221.3
CHF
Average target price
279.4
CHF
Spread / Average Target
+26.25%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -9.08% | 197B | |
| +32.95% | 700B | |
| -4.97% | 358B | |
| +18.83% | 330B | |
| +3.54% | 287B | |
| +15.70% | 236B | |
| +6.68% | 202B | |
| +6.70% | 161B | |
| -1.81% | 157B | |
| +3.70% | 124B |
- Stock Market
- Equities
- ROG Stock
- News Roche Holding AG
- Transcript : Roche Holding AG, Q3 2023 Sales/ Trading Statement Call, Oct 19, 2023